Comparative Pharmacology
Head-to-head clinical analysis: DANAZOL versus ORETON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANAZOL versus ORETON.
DANAZOL vs ORETON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Danazol is a synthetic androgen derived from ethisterone that suppresses pituitary-ovarian axis by inhibiting gonadotropin release, leading to decreased estrogen and progesterone levels. It also has weak androgenic and progestational activity.
Androgen receptor agonist; binds to androgen receptors, stimulating protein synthesis, growth of male reproductive tissues, and development of secondary sexual characteristics.
300-600 mg orally twice daily; maximum 800 mg/day
Testosterone enanthate 50-400 mg IM every 2-4 weeks.
None Documented
None Documented
Terminal elimination half-life is 4-4.5 hours; clinical context: requires multiple daily dosing to maintain therapeutic levels.
Clinical Note
moderateDanazol + Tolbutamide
"The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Rosiglitazone
"The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Pioglitazone
"The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Saxagliptin
8 hours for testosterone; clinical context: requires daily or weekly dosing for replacement therapy
Primarily hepatic metabolism; approximately 60% excreted in feces, 30% in urine as metabolites.
Renal (90% as metabolites, 5% unchanged), biliary/fecal (10%)
Category C
Category C
Androgen/Antigonadotropin
Androgen
"The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Danazol."